Efficacy of a novel fusion protein on nasal polyps to control eosinophilic sinusitis.

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K18328
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Kansai Medical University
• Principal Investigator: SHIMIZU Minaki 関西医科大学, 医学部, 助教 (60714962)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: ECRS / 好酸球性副鼻腔炎 / 鼻茸

Outline of Final Research Achievements

In order to develop new therapeutic methods for overcoming ECRS, we have investigated the intranasal tissue environment of affected patients in vitro. So far, when comparing nasal polyps mucosa, which is one of the characteristics of eosinophilic sinusitis, with tissues of other parts of the same patient, significant differences in cytokine expression were observed. Moreover, it was clarified that different cell types in the nasal tissue have different expression levels of cytokines. Therefore, it was clarified that stimulation of cells in nasal tissue with typical inflammatory cytokines enhances the production of multiple cytokines. In addition, it was found that the production of other cytokines induced by inflammatory cytokines was suppressed by neutralizing antibodies.

Free Research Field

耳鼻咽喉科領域

Academic Significance and Societal Importance of the Research Achievements

ECRSは難病疾患に指定された経緯をもつ。ECRS患者は、癌やアレルギー性鼻炎とともに急増している。唯一ステロイド治療は一定の効果があるが、長期のステロイド投与はその副作用の点で困難である。手術的加療も行われるがしばしば再発し、いまだ病態の解明や治療法の確立には至っていない。このような国民を悩ます疾患のコントロールを目指した病態の一端が確認できたことは意義が大きい。